The LDL Hypothesis (BLA S2E4)

The LDL Hypothesis  (BLA S2E4)

Do you ever wonder why we think that LDL plays such a big role in atherosclerosis, and why we try to lower it? Well in this episode we dive deep into the landmark studies that paved the way for the LDL hypothesis.

00:00 - Start
00:23 - Introduction
01:02 - Importance
02:02 - LDL review
04:09 - Atherosclerosis Review
06:14 - History of LDL/lipid Research
09:14 - 3 types of supporting data
12:14 - Framingham Studies
13:31 - 4S Trial
14:34 - West of Scotland Study
15:24 - CARE Trial
16:37 - Heart Protection Study
17:03 - PROSPER Study
17:53 - PROVE IT - TIMI 22 Trial
19:03 - IDEAL Trial
20:12 - REVERSAL Trial
21:15 - ASTEROID Trial
22:18 - IMPROVE-IT
23:52 - DESCARTES Study
25:17 - OSLER 1/2 Trials
27:03 - GLAGOV Study
27:43 - LDL lowering and risk reduction meta analysis
28:41 - FOURIER Trial
29:52 - Further lowering LDL meta analysis
31:11 - CLEAR HARMONY Trial
32:23 - What is optimal LDL study
33:58 - Mendelian Randomization
36:22 - Putting it all together
38:43 - Summary


Austin, Peter C., and Muhammad M. Mamdani. “Impact of the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22/Reversal of Atherosclerosis with Aggressive Lipid Lowering Trials on Trends in Intensive versus Moderate Statin Therapy in Ontario, Canada.” Circulation 112, no. 9 (August 30, 2005): 1296–1300.    

Blom, Dirk J., Tomas Hala, Michael Bolognese, Michael J. Lillestol, Phillip D. Toth, Lesley Burgess, Richard Ceska, et al. “A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia.” New England Journal of Medicine 370, no. 19 (May 8, 2014): 1809–19.    

Cannon, Christopher P., Michael A. Blazing, Robert P. Giugliano, Amy McCagg, Jennifer A. White, Pierre Theroux, Harald Darius, et al. “Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.” New England Journal of Medicine 372, no. 25 (June 18, 2015): 2387–97.    

Cannon, Christopher P., Eugene Braunwald, Carolyn H. McCabe, Daniel J. Rader, Jean L. Rouleau, Rene Belder, Steven V. Joyal, Karen A. Hill, Marc A. Pfeffer, and Allan M. Skene. “Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes.” New England Journal of Medicine 350, no. 15 (April 8, 2004): 1495–1504.    

Chhatriwalla, Adnan K., Stephen J. Nicholls, and Steven E. Nissen. “The ASTEROID Trial: Coronary Plaque Regression with High-Dose Statin Therapy.” Future Cardiology 2, no. 6 (November 2006): 651–54.    

Dawber, Thomas R., Felix E. Moore, and George V. Mann. “II. Coronary Heart Disease in the Framingham Study.” American Journal of Public Health and the Nations Health 47, no. 4 Pt 2 (April 1957): 4–24.    

Downs, J. R., M. Clearfield, S. Weis, E. Whitney, D. R. Shapiro, P. A. Beere, A. Langendorfer, E. A. Stein, W. Kruyer, and A. M. Gotto. “Primary Prevention of Acute Coronary Events with Lovastatin in Men and Women with Average Cholesterol Levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.” JAMA 279, no. 20 (May 27, 1998): 1615–22.    

Goldstein, Joseph L., and Michael S. Brown. “A Century of Cholesterol and Coronaries: From Plaques to Genes to Statins.” Cell 161, no. 1 (March 26, 2015): 161–72.    

Heart Protection Study Group Collaborative Group. (2007). Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. Journal of Vascular Surgery, 45(4), 645-654.e1.  

LaRosa, John C., Scott M. Grundy, David D. Waters, Charles Shear, Philip Barter, Jean-Charles Fruchart, Antonio M. Gotto, et al. “Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease.” The New England Journal of Medicine 352, no. 14 (April 7, 2005): 1425–35.    

Lewis, S. J., F. M. Sacks, J. S. Mitchell, C. East, S. Glasser, S. Kell, R. Letterer, et al. “Effect of Pravastatin on Cardiovascular Events in Women after Myocardial Infarction: The Cholesterol and Recurrent Events (CARE) Trial.” Journal of the American College of Cardiology 32, no. 1 (July 1998): 140–46.    

“MRC/BHF Heart Protection Study of Cholesterol Lowering with Simvastatin in 20 536 High-Risk Individuals: A Randomised Placebocontrolled Trial.” The Lancet 360, no. 9326 (July 6, 2002): 7–22.    

Nicholls, Stephen J., Rishi Puri, Todd Anderson, Christie M. Ballantyne, Leslie Cho, John J. P. Kastelein, Wolfgang Koenig, et al. “Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.” JAMA 316, no. 22 (December 13, 2016): 2373–84.    

Nissen, Steven E. “Effect of Intensive Lipid Lowering on Progression of Coronary Atherosclerosis: Evidence for an Early Benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Trial.” The American Journal of Cardiology 96, no. 5A (September 5, 2005): 61F-68F.    

Nissen, Steven E., Stephen J. Nicholls, Ilke Sipahi, Peter Libby, Joel S. Raichlen, Christie M. Ballantyne, Jean Davignon, et al. “Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis: The ASTEROID Trial.” JAMA 295, no. 13 (April 5, 2006): 1556–65.    

O’Keefe, James H., Loren Cordain, William H. Harris, Richard M. Moe, and Robert Vogel. “Optimal Low-Density Lipoprotein Is 50 to 70 Mg/Dl: Lower Is Better and Physiologically Normal.” Journal of the American College of Cardiology 43, no. 11 (June 2, 2004): 2142–46.    

Pedersen, T. R., J. Kjekshus, K. Berg, T. Haghfelt, O. Faergeman, G. Faergeman, K. Pyörälä, et al. “Randomised Trial of Cholesterol Lowering in 4444 Patients with Coronary Heart Disease: The Scandinavian Simvastatin Survival Study (4S). 1994.” Atherosclerosis. Supplements 5, no. 3 (October 2004): 81–87.    

Pedersen, Terje R., Ole Faergeman, John J. P. Kastelein, Anders G. Olsson, Matti J. Tikkanen, Ingar Holme, Mogens Lytken Larsen, et al. “High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention after Myocardial Infarction: The IDEAL Study: A Randomized Controlled Trial.” JAMA 294, no. 19 (November 16, 2005): 2437–45.    

“Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels.” New England Journal of Medicine 339, no. 19 (November 5, 1998): 1349–57.    

Ridker, Paul M, Eleanor Danielson, Francisco A.H. Fonseca, Jacques Genest, Antonio M. Gotto, John J.P. Kastelein, Wolfgang Koenig, et al. “Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein.” New England Journal of Medicine 359, no. 21 (November 20, 2008): 2195–2207.    

Robinson, Jennifer G., Michel Farnier, Michel Krempf, Jean Bergeron, Gérald Luc, Maurizio Averna, Erik S. Stroes, et al. “Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events.” New England Journal of Medicine 372, no. 16 (April 16, 2015): 1489–99.    

Sabatine, Marc S., Robert P. Giugliano, Anthony C. Keech, Narimon Honarpour, Stephen D. Wiviott, Sabina A. Murphy, Julia F. Kuder, et al. “Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.” New England Journal of Medicine 376, no. 18 (May 4, 2017): 1713–22.    

Sabatine, Marc S., Robert P. Giugliano, Stephen D. Wiviott, Frederick J. Raal, Dirk J. Blom, Jennifer Robinson, Christie M. Ballantyne, et al. “Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events.” New England Journal of Medicine 372, no. 16 (April 16, 2015): 1500–1509.    

Sabatine, Marc S., Stephen D. Wiviott, KyungAh Im, Sabina A. Murphy, and Robert P. Giugliano. “Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-Analysis.” JAMA Cardiology 3, no. 9 (September 1, 2018): 823–28.    

Schwartz, Gregory G., P. Gabriel Steg, Michael Szarek, Deepak L. Bhatt, Vera A. Bittner, Rafael Diaz, Jay M. Edelberg, et al. “Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.” New England Journal of Medicine 379, no. 22 (November 29, 2018): 2097–2107.    

Shepherd, J. “The West of Scotland Coronary Prevention Study: A Trial of Cholesterol Reduction in Scottish Men.” The American Journal of Cardiology 76, no. 9 (September 28, 1995): 113C-117C.    

Shepherd, J., S. M. Cobbe, I. Ford, C. G. Isles, A. R. Lorimer, P. W. MacFarlane, J. H. McKillop, and C. J. Packard. “Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia. West of Scotland Coronary Prevention Study Group.” The New England Journal of Medicine 333, no. 20 (November 16, 1995): 1301–7.    

Shepherd, James, Gerard J. Blauw, Michael B. Murphy, Edward L. E. M. Bollen, Brendan M. Buckley, Stuart M. Cobbe, Ian Ford, et al. “Pravastatin in Elderly Individuals at Risk of Vascular Disease (PROSPER): A Randomised Controlled Trial.” Lancet (London, England) 360, no. 9346 (November 23, 2002): 1623–30.    

Silverman, Michael G., Brian A. Ference, Kyungah Im, Stephen D. Wiviott, Robert P. Giugliano, Scott M. Grundy, Eugene Braunwald, and Marc S. Sabatine. “Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-Analysis.” JAMA 316, no. 12 (September 27, 2016): 1289–97.    

Tikkanen, Matti J., Michael Szarek, Rana Fayyad, Ingar Holme, Nilo B. Cater, Ole Faergeman, John J. P. Kastelein, et al. “Total Cardiovascular Disease Burden: Comparing Intensive with Moderate Statin Therapy Insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) Trial.” Journal of the American College of Cardiology 54, no. 25 (December 15, 2009): 2353–57.    

Waters, David D., John R. Guyton, David M. Herrington, Mary P. McGowan, Nanette K. Wenger, Charles Shear, and TNT Steering Committee Members and Investigators. “Treating to New Targets (TNT) Study: Does Lowering Low-Density Lipoprotein Cholesterol Levels below Currently Recommended Guidelines Yield Incremental Clinical Benefit?” The American Journal of Cardiology 93, no. 2 (January 15, 2004): 154–58.

*Disclaimer* This video is for entertainment, education, and informational purposes only. The topics  discussed should not solely be used to diagnose, treat , or prevent any condition.  The information presented here was created with an evidence based approach, but you please keep in mind that science is always changing and at the time of listening to this there may some new data that makes this information incomplete or inaccurate. Always seek the advice of your personal physician or qualified health care provider for questions regarding any medical condition.